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I n May 2014, a panel was assembled for the plenary session ofthe annual Accelerating Anticancer Agent Development andValidation (AAADV) Workshop in Bethesda, Maryland, to fo-
cus on “Patient-reported outcomes (PROs) and patient-focused drug
development.” The members of that panel constitute the authors
of this piece, and each provided his or her perspective as a repre-
sentative of the pharmaceutical industry, the Food and Drug Ad-
ministration (FDA), the PRO Consortium (a collaborative effort be-
tween FDA, industry, and the Critical Path Institute to fill PRO
measurement gaps),1 clinicians, and patients. Assembly of this panel
by FDA was prompted by the observation that data reported di-
rectly by patients about their symptoms and functioning are rarely
included in oncology drug labeling in the United States.2 This stands
in contrast to oncology labeling in Europe and to nononcology la-
beling in the United States, where PROs are more commonly
included.3
Although FDA released a guidance document in 2009 specify-
ing the types of evidence and documentation required for PRO mea-
sures to support regulatory approval or labeling claims in the United
States,4 these principles have rarely been successfully applied in on-
cology drug development programs. Patient-reported outcome end
points are frequently an afterthought in the design of industry-
sponsored clinical trials in oncology and are deemphasized relative
to end points related to survival, imaging, and biomarkers. Yet sur-
vival advantages of cancer drugs are frequently modest, on the or-
der of weeks or months, and radiographic or biomarker-related end
points can be of questionable clinical relevance. Cancer drugs of-
ten carry substantial toxicities that may affect how people feel and
function. It would therefore be valuable to include information on
patient symptoms and function in clinical trials more frequently, and
it seems counter-intuitive that PRO end points are not central in the
evaluation of cancer drugs.
In this article, perspectives are provided regarding the ratio-
nale, barriers, and strategies for integrating PRO end points and guid-
ance principles into cancer drug development and US labeling. The
goal is to demonstrate differences and common ground between
stakeholders, and suggest steps forward. It is acknowledged that this
article reflects individual perspectives of the authors as represen-
tatives of their stakeholder categories and may not reflect the over-
all or complete perspectives of each stakeholder group.
Industry Perspective
Whereas the recommendations in the 2009 FDA guidance4 on the
use of PROs in drug development have increased the overall rigor
of PRO measurement in clinical trials, what many believe to be un-
attainable standards, inconsistency in implementation across the
Data reported directly by patients about how they feel and function are rarely included in
oncology drug labeling in the United States, in contrast to Europe and to nononcology
labeling in the United States, where this practice is more common. Multiple barriers exist,
including challenges unique to oncology trials, and industry’s concerns regarding cost,
logistical complexities, and the Food and Drug Administration’s (FDA’s) rigorous application of
its 2009 guidance on the use of patient-reported outcome (PRO) measures. A panel
consisting of representatives of industry, FDA, the PRO Consortium, clinicians, and patients
was assembled at a 2014 workshop cosponsored by FDA to identify practical
recommendations for overcoming these barriers. Key recommendations included increasing
proactive encouragement by FDA to clinical trial sponsors for including PROs in drug
development programs; provision of comprehensive PRO plans by sponsors to FDA early in
drug development; promotion of an oncology-specific PRO research agenda; development of
an approach to existing (“legacy”) PRO measures, when appropriate (focused initially on
symptoms and functional status); and increased FDA and industry training in PRO
methodology. FDA has begun implementing several of these recommendations.
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various FDA reviewing divisions, and the time taken to review
the evidence (thus delaying the development of new therapies)
have become a cause for frustration within the industry.5,6
Data suggest that FDA, and the Office of Hematology and
Oncology Products (OHOP) in particular, includes PROs less com-
monly in their labels than their European oncology counterparts,
or US nononcology review divisions.3,7 Although PRO-based
labeling claims are granted to approximately one-quarter of
all new drugs in the United States, it is a rare occurrence for
oncology-related therapies.7 For new oncology-related com-
pounds approved between 2006 and 2013 by FDA, PRO-based
labeling claims were granted to only 1 of 43 compounds. This
compares to 14 of 42 oncology products approved by the Euro-
pean regulators.7
Within this context, the industry faces major challenges when
it comes to integrating PRO measurement in oncology clinical trials:
• Despite small improvements in overall survival rates, both regu-
lators and the industry continue to prioritize survival-based end
points rather than end points based on patient experience.2
• Whereas developing new disease-specific PRO measures to sat-
isfy US regulators can take years, the oncology drug develop-
ment programs often go through an accelerated drug approval pro-
cess and generally have compressed development timelines. Of the
17 cancer-related new molecular entities approved by FDA in 2013
and 2014, less than one-third were based on double-blind ran-
domized clinical trials and more than half of approvals went through
the accelerated approvals program. Such hurdles, along with the
challenges of integrating PRO measures in multinational clinical
trials8 and the lack of precedents by US regulators to recognize PRO
data to be worthy of labeling claims for oncology compounds,7 as
well as the perceived indifference shown by the oncology review-
ing divisions toward PRO data, discourage sponsors from integrat-
ing PRO end points as part of their evidence package to satisfy US
regulators.
• Sponsors grapple with small patient numbers, very sick or termi-
nally ill patients, high failure rates, and single-arm studies unique
to the development of new therapies in oncology.
Faced with such challenges, it is not a surprise that sponsors in-
clude the minimum evidence required to satisfy regulators. Given
the relatively high probability of label claims from European regu-
lators, and given the challenges of including disease-specific PRO
measures in clinical trials to satisfy FDA, sponsors may include off-
the-shelf but well-tested measures such as the European Organi-
zation for Research and Treatment of Cancer QLQ-C309 in their con-
firmatory clinical trials. Data from such measures, although they may
not meet current FDA expectations for labeling, are methodologi-
cally rigorous and routinely satisfy regulators and payers in Europe,
provide data for publication, and are informative for other stake-
holders including advisory committees, patients, payers, patient ad-
vocacy groups, and clinicians.10,11
It is worth noting that whereas many FDA review divisions rou-
tinely expect sponsors to include PRO data as part of the evidence
package to assess the efficacy of new therapies, the oncology
reviewing divisions rarely do. In the future, ideally medical review-
ers within these divisions would encourage sponsors to assess
PROs in drug development programs and work collaboratively with
sponsors to design a PRO measurement plan that is robust and
feasible.
FDA Perspective
The 2012 Food and Drug Administration Safety and Innovation Act
makes it clear that patient-focused drug development is a priority
for Congress, FDA, and the American people.12 Whereas there is little
argument that measuring a patient’s symptoms or function is im-
portant and can be a direct measure of clinical benefit, the chal-
lenge lies in how the patient perspective is most accurately cap-
tured. FDA requires that substantial evidence be presented to
support a labeling or marketing claim of treatment benefit and this
necessitates adequate and well-controlled studies using well-
defined and reliable assessments.13 When evaluating whether a PRO
instrument is adequate to support labeling, the agency places a
strong emphasis on content validity (ie, that the instrument mea-
sures what it is intended or purported to measure). Content valid-
ity is critical in the regulatory setting, where regulators have a duty
to ensure that drug labeling is not false or misleading. Unfortu-
nately, many existing PRO measures and trial designs proposed to
FDA have had substantial flaws that have precluded their inclusion
in the product label.
To facilitate and standardize best practices for PRO instrument
development and trial conduct, FDA finalized a 2009 guidance on
the use of PROs for medical product development to support label-
ing claims.4 In addition to content validity, the guidance describes
measurement properties (eg, reliability, construct validity, ability to
detect change) that should be examined to ensure that an instru-
ment can provide a quantitative assessment of a drug’s effects. Im-
portant trial design considerations are also discussed, including the
frequency and timing of assessments, administration mode (eg, pa-
per, electronic), and handling of missing data. All of these issues con-
tribute to the adequacy and interpretability of PRO data to support
labeling claims, and as with any other end point, if the intent is to
make an efficacy claim (eg, drug X improves pain), PRO end points
should be prespecified in the statistical analysis plan, with appro-
priate adjustments for multiplicity. Given the complexity of PRO mea-
sure development, FDA encourages sponsors to engage FDA in dis-
cussions about these end points as early as possible.
Many concerns voiced by our fellow panelists relate to the per-
ceived strict adherence to FDA PRO guidance. The PRO guidance is a
framework for optimal instrument development, trial design, and
At a Glance
• Data reported directly by patients about how they feel are rarely
included in cancer drug labeling.
• Barriers include methodological challenges, cost and logistics,
FDA guidance on patient-reported outcome (PRO) measures,
and communication.
• An expert panel identified practical recommendations for
overcoming these barriers.
• Proactive role for FDA in encouraging PRO end points
• Provision of comprehensive PRO measurement plans by FDA
• Characterization and mitigation of the effect of open-label
trial designs
• Research on patterns and cases of missing data
• Development of best practices for statistical analyses of PRO
data
• Increased FDA and industry training in PRO methodology
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analysis of PRO data and was written to address all therapeutic areas.
We realize that although incorporating all of the principles of the PRO
guidance would be ideal, there are cases in which regulatory flexibil-
ity might be exerted, particularly in the oncology setting. For in-
stance, we recognize that many oncology trials are performed in an
open-label fashion when blinding is considered infeasible. Lack of
blinding is a substantial limitation; however, PRO data might still be
convincing in the context of a large magnitude of effect demonstrated
in the setting of thoughtful trial design and conduct with very little
missing data. Limitations of PRO data might also be described in FDA
labeling (eg, extent of missing data, open-label nature of a study) to
better inform physicians and patients when interpreting results.
Looking forward, it is clear that the successful integration of PROs
into oncology product labels will not be accomplished by any one single
entity. FDA does not itself develop PRO instruments or conduct clini-
cal trials, and therefore collaborative work is needed to identify a clear
research agenda supported by all relevant stakeholders. We must char-
acterize and mitigate the challenges that we face in the oncology set-
ting, including adequacy of instruments, open-label trials, single-
arm trials, missing data, and best practices for statistical analyses. It
all starts with well-defined and reliable PRO instruments; and with ap-
propriate supportive data, the path forward may include the modifi-
cation of existing legacy measures that are not considered fit for pur-
pose in their present form. Another underutilized opportunity is the
use of the FDA Center for Drug Evaluation and Research (CDER) drug
development tool Clinical Outcome Assessment Qualification pro-
gram, which provides a forum for FDA to work with external instru-
ment developers to provide consultation and advice in order to de-
velop and qualify publicly available outcome assessments for use
across multiple clinical trials. FDA encourages all parties interested in
PRO instrument development to engage with CDER through this pro-
gram to increase the number of publicly available tools that are avail-
able to support product labeling.
FDA’s OHOP and CDER’s Study Endpoints and Labeling Devel-
opment staff acknowledge the frustration among patients, drug de-
velopers, and outcomes researchers and are themselves disap-
pointed by the low level of attention paid to PRO integration in many
oncology clinical trial designs. For our part, we have put substantial
effort into optimizing communication both between Study End-
points and Labeling Development and OHOP and between FDA and
stakeholders to improve consistency of PRO advice. There is a re-
newed focus on identifying key elements of the patient perspec-
tive that can be described in all oncology trials, and it is our expec-
tation that we will start to see the quality of data necessary to allow
for inclusion in the FDA label. There is reason to be optimistic that
we can all do better, and FDA is dedicated to working with all stake-
holders to address these issues.
Patient Representative Perspective
When I (C.G.) received a diagnosis of breast cancer 19 years ago, I
struggled with my role in deciding on optimal treatment, with very
limited relevant information and no access to the Internet or peer
support. Two decades later, patients with cancer continue to struggle
in their broadened decision-making roles.
As we move to invoke a “patient-centered” health care system,
patients who already struggle to navigate life-saving treatment de-
cisions will soon be expected to drive their own care. Patient-
reported outcomes data aggregated from prior trials are necessary
to enable people to make rational decisions about treatments that bal-
ance impact on survival, as well as symptoms and overall quality of
life and financial impact. As a community of patients and research-
ers, we can no longer tolerate the lack of routinely and thoughtfully
incorporated PRO evidence from cancer clinical trials.
Patients will always strive for survival as their goal and as a clini-
cal end point. When faced with a decision to choose between treat-
ments that have shown very modest benefit without extending life,
they need to know what they can expect to feel and how they can
expect to function.
Without systematically collected PRO data, patients are forced
to fill information gaps by searching the Internet, where they can
connect instantly with individuals—patient peers and clinical trial par-
ticipants—who are eager to help with real-time “peer-reported out-
comes” and personal experiences. With little effort, patients
already access disease-focused websites, discussion boards, Face-
book posts, blogs, and Twitter feeds to find anecdotes about
specific therapies, adverse events, quality of life improvements,
treatment failures, and extraordinary benefits. But the patients
posting and consuming these anecdotal data cannot assess accu-
racy or generalizability.
As a patient, I find it hard to understand how FDA can continue
to evaluate the potential benefits and harms of cancer drugs that are
toxic, with survival benefits measured only in days or weeks, with-
out a comprehensive understanding of patient experiences elicited
through PROs. Patients are being encouraged to demand more from
clinical trials,14 and in turn we need to demand more from FDA, in-
dustry, and PRO measure developers. FDA should work with trial spon-
sors to ensure that they routinely collect and provide PRO informa-
tion as the default expected approach for every new drug
application—so that this information can be used not only as part of
the application but also so that subsequent patients can understand
the potential impact on their lives. Drug developers need to collabo-
rate with patients and with FDA to ensure that they are capturing in-
formation that is meaningful to understanding how patients feel and
function while receiving new therapies. Patient-centered care can-
not be delivered without patient-centered outcomes information.
PRO Consortium Perspective
Although there is considerable frustration among a variety of stake-
holders with the lack of PRO-based end points in cancer trials, FDA’s
CDER has taken steps in the right direction. CDER took a leadership
role in forming the Patient-Reported Outcome Consortium in 2008
in conjunction with the Critical Path Institute and the pharmaceu-
tical industry.1 The mission of the PRO Consortium is to develop and
achieve FDA qualification15 of PRO measures for use in clinical trials
in which PRO-based efficacy end points are used to support prod-
uct labeling claims. Currently, 27 pharmaceutical firms are working
collaboratively within the PRO Consortium to identify and fill PRO
measurement gaps. The goals of the PRO Consortium are to
• Enable precompetitive collaboration that includes FDA input and
expertise
• Avoid development of multiple PRO measures for the same
purpose
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• Share costs of developing new PRO measures
• Develop qualified, publicly available PRO measures
• Facilitate FDA review of medical products by standardizing PRO
end points
In conjunction with FDA, the PRO Consortium member firms
identified non–small-cell lung cancer (NSCLC), breast cancer, ad-
vanced ovarian cancer, and colorectal cancer as diseases for which
there was sufficient need and interest in pursuing qualification of a
PRO-based end point measure. At present, the NSCLC Working
Group is the only active cancer-related working group within the PRO
Consortium. The Breast Cancer Working Group was established but
put on hold, and working groups for advanced ovarian cancer and
colorectal cancer were not established pending the outcome of the
NSCLC Working Group’s efforts. Among other impediments (eg, chal-
lenges associated with achieving consensus within a multicom-
pany collaboration), the NSCLC Working Group and FDA have ex-
pended an inordinate amount of time and effort interacting in regard
to the target population (ie, stage, treatment status/pathways, and
performance status) for the measure’s context of use. Members of
the PRO Consortium want to be sure that qualification of a PRO mea-
sure for NSCLC trials is possible before investing the considerable
resources necessary to develop measures for the other cancer sites.
A number of obstacles have led to concern that the hurdle for
PRO end point measures for oncology trials is too high. For one, even
though blinding in oncology trials is often impossible to achieve, FDA
communicated to the NSCLC Working Group that “even well-
defined and reliable symptom assessments are rarely credible in a
study where patients are unblinded to study treatment” (written
communication, September 2010). In addition, FDA has been resis-
tant to the measurement of fatigue, a common and potentially de-
bilitating symptom of cancer and its treatment. In these cases, it
seems that FDA is allowing the perfect to be the enemy of the good
(enough).
Patient-reported outcome instruments measure how patients
feel and/or function, which are more direct assessments of treat-
ment benefit than many other end points. Hence, it is critical that
obstacles to the use of PRO-based end points in oncology trials be
addressed and minimized through more effective and construc-
tive dialog between the primary stakeholders (ie, patients, clini-
cians, industry, FDA, contract research organizations, and PRO in-
strument developers).
Concluding Remarks
This article presents relatively uncensored perspectives, and in some
cases frustrations, of different stakeholder representatives striving
to incorporate information in oncology drug development about the
impact of treatments on the patient experience. A cycle of nega-
tive feedback exists between FDA and industry, in which FDA as-
serts that industry puts little effort into developing rigorous PRO end
points and industry asserts that it is not worth the effort because
FDA’s bar is too high. All of us note the importance of breaking this
cycle to ensure progress in making oncology drug development more
patient centered.
The Box provides specific recommendations derived from the
common threads of stakeholder perspectives. Areas of particular em-
phasis include improving communication between the industry, FDA,
and patient groups; early consideration of integrating PROs in drug
development programs to facilitate any needed development work;
and expansion of PRO expertise in the industry and FDA. It is often
expected that a given PRO measure will be developed or evaluated
in the planned context of use in order to be fit for purpose in a given
drug development program or pivotal trial. For example, if a mea-
sure was developed for measuring symptoms in breast cancer and now
is of interest in prostate cancer, some additional development work
might be expected, for example, qualitative work to ensure that the
concepts or questions are meaningful and relevant. The extent of ad-
ditional work will depend on how similar or different the new popu-
lation is from the prior population. If there are substantial differ-
ences, a new or different measure may need to be developed and/or
tested. Because it may require some lead time to do such work, early
discussion between sponsors and FDA is important to avoid any de-
lays associated with such work and to facilitate potential inclusion of
such work within clinical studies (eg, during phase 2, but can be con-
sidered as early as pre–Investigational New Drug Application).
Box. Specific Recommended Actions to Increase Integration
of Patient-Reported Outcomes (PROs) in Oncology Drug
Development Programs and US Product Labels
Medical reviewers within the Food and Drug Administration’s
(FDA’s) Office of Hematology and Oncology Products should be
more proactive in encouraging sponsors to include the assessment
of PROs in their drug development programs.
Trial sponsors should provide thoughtful and comprehensive
proposals for PRO measures and data collection methods and
should describe deviations from the PRO guidance with a rationale
for why these deviations may be acceptable in their trial context.
Early discussions with FDA can facilitate this process.
Patient-reported outcomes stakeholders should identify a clear
research agenda to characterize and mitigate known limitations in
the oncology setting including adequacy of existing instruments,
the effect of open-label trial designs, patterns and causes of
missing data, and best practices for statistical analyses.
A systematic approach to analyzing existing (“legacy”)
questionnaires should be developed as a basis for FDA to assess and
publicly endorse those that meet acceptable criteria for use in
oncology registration trials toward labeling, with the understanding
that there may not be perfect adherence to FDA guidance
principles.
Stakeholders from industry, academia, patient groups, and FDA
should work together to identify or develop PRO measures of
outcomes that are important to patients (eg, physical function and
fatigue) that could be endorsed as acceptable by FDA for cancer
drug product labeling.
The FDA should support training of additional FDA personnel to
accelerate dialog with product developers and other stakeholders
about the development, qualification, implementation, and
analysis of PRO measures. Inclusion of individuals with PRO
expertise within FDA clinical review divisions will facilitate
balancing methodological concerns with a realistic understanding
of clinical issues and logistical challenges associated with oncology
clinical trials.
Industry and academia should work together to develop training
programs for those interested in PRO assessments for use in the
regulatory setting and should consider including patient advocates
in these initiatives.
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As a part of FDA’s Patient-Focused Drug Development pro-
gram, a number of workshops are being sponsored to openly dis-
cuss barriers to bringing the patient perspective into drug develop-
ment more broadly, and to consider ways to implement solutions.
Standardization of best practices across the PRO research con-
tinuum—from identification of concepts to measure, to instrument
selection, to trial design and conduct, to data analysis and presen-
tation—will be critical to success. It is our hope that the frequency
of important and interpretable PRO data in oncology drug labels will
increase in the coming years as a result of these efforts.
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